US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Karyopharm Therapeutics Inc. - Common Stock
(NQ:
KPTI
)
0.6050
+0.0050 (+0.83%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Karyopharm Therapeutics Inc. - Common Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
August 25, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
August 18, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
August 11, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
August 04, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Registration Momentum Builds Across the Oncology Pipeline
February 17, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
USA News Group
Via
GlobeNewswire